0001654954-17-008693.txt : 20170921 0001654954-17-008693.hdr.sgml : 20170921 20170921172855 ACCESSION NUMBER: 0001654954-17-008693 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170919 FILED AS OF DATE: 20170921 DATE AS OF CHANGE: 20170921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Steiner Robert D CENTRAL INDEX KEY: 0001717553 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33004 FILM NUMBER: 171096406 MAIL ADDRESS: STREET 1: C/O ACER THERAPEUTICS INC. STREET 2: 222 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Acer Therapeutics Inc. CENTRAL INDEX KEY: 0001069308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 760333165 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 THIRD STREET STREET 2: SUITE #2240 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (844) 902-6100 MAIL ADDRESS: STREET 1: 222 THIRD STREET STREET 2: SUITE #2240 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Opexa Therapeutics, Inc. DATE OF NAME CHANGE: 20060616 FORMER COMPANY: FORMER CONFORMED NAME: PharmaFrontiers Corp. DATE OF NAME CHANGE: 20051011 FORMER COMPANY: FORMER CONFORMED NAME: PHARMAFRONTIERS CORP DATE OF NAME CHANGE: 20040816 4 1 section16.xml PRIMARY DOCUMENT X0306 4 2017-09-19 0001069308 Acer Therapeutics Inc. ACER 0001717553 Steiner Robert D 222 THIRD STREET SUITE #2240 CAMBRIDGE MA 02142 true Chief Medical Officer Nonqualified Stock Option (right to buy) 2.55 2017-09-19 4 J false 40000 A 2026-04-05 Common Stock 40000 40000 D Received in connection with the Issuer's business combination (the "Merger") with what was then known as "Acer Therapeutics Inc." ("Private Acer") in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated June 30, 2017 among the Issuer, Opexa Merger Sub, Inc. and Private Acer, in exchange for an option to acquire 40,000 shares of common stock of Private Acer. Option vests in eight equal quarterly installments beginning on January 1, 2016. /s/ Daniel S. Clevenger, Attorney-in-Fact for Robert Steiner 2017-09-21